Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab

Background Tumor necrosis factor inhibitor therapy for rheumatoid arthritis (RA) patients reduces disease activity, but little is known about the factors that correlate with continuation of remission. To identify demographics and clinical characteristics associated with achievement and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab (ADA).